

Correction: *Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial*

Balanescu AR, Citera G, Pascual-Ramos V, *et al.* Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial. *Ann Rheum Dis* 2022;81:1491–503. doi:10.1136/ard-2022-222405.

In Table 3, there was a typographical error in the upper confidence interval of the hazard ratio for ‘history of extra-articular disease: yes versus no’ as a risk factor for serious infection events with tofacitinib 5 mg two times per day. The incorrect value was 1.19, this has now been corrected to 1.91.

The value has now been corrected in the online publication.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2023;82:e219. doi:10.1136/ard-2022-222405corr1

